Better Health for All
0
Valneva's entire business, representing 100% of its €169.6 million total revenue in 2024, is dedicated to developing and commercializing prophylactic vaccines for infectious diseases with unmet medical needs, such as chikungunya, cholera, Japanese encephalitis, and Lyme disease.
1
The company has no revenue from products with negative health outcomes. Valneva supplied 40,000 doses of its chikungunya vaccine to La Réunion in response to an outbreak in March 2025.
2
However, French health authorities suspended the use of this vaccine in persons aged 65 and older on April 25, 2025, following reports of three serious adverse events, including one death, in La Reunion, though causality has not been definitively established.
3
Valneva has agreements with Serum Institute of India and Instituto Butantan to supply its chikungunya vaccine at an affordable price to public health markets in Low- and Middle-Income Countries (LMICs), and two-thirds of its commercial vaccines have access routes for LMICs.
4
The company aims to enable access to its single-shot chikungunya vaccine in Brazil and India by 2026 through local manufacturing and technology transfers.
5
Valneva invested €74.143 million in R&D in 2024, which is 43.7% of its total revenue.
6
The company's risk transparency is impacted by forward-looking statements and a lack of specific, quantifiable risk disclosures.
7
Valneva's mental health initiatives are limited to providing a smartphone app for psychosocial risks in France and general resources in Scotland.
8
The company also has a policy on animal welfare and aims for transparency in clinical trial data, but specific ethical conduct details are not extensively provided.
9
Fair Money & Economic Opportunity
0
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines. Its core business does not involve lending, insuring, moving, or storing money for consumers, nor does it offer financial services or products.
1
Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its operations.
2
The provided articles focus on the company's financial performance, regulatory approvals, and clinical trials related to vaccines, offering no evidence of engagement in financial services.
3
Fair Pay & Worker Respect
10
In 2024, 71.6% of Valneva's global workforce was covered by collective bargaining agreements.
1
The company's accident frequency rate in France was 18.8 per 200,000 hours in 2023.
2
Valneva reported a gender pay index of 3% in 2023, indicating a pay equity ratio of 0.97.
3
Voluntary employee turnover was 23% in 2023.
4
The company has not reported any substantiated labor-law or human-rights violations in the past three years. Additionally, 99% of the workforce is covered by comprehensive health and wellness coverage.
Fair Trade & Ethical Sourcing
-20
Valneva reported no substantiated forced or child labor incidents in its operations or supply chain for 2023 and no findings for 2024.
1
The company's Business Partners Code of Conduct is mandatory for key business partners, and in 2024, 80% of suppliers were covered by supplier evaluation, indicating that a significant portion of contracts include enforceable ethical-sourcing clauses.
2
Honest & Fair Business
-20
Valneva has a Whistleblower Policy, a 24/7 anonymous and secured compliance helpline, and a Non-Retaliation and Non-Retribution Policy, vowing since 2016 to protect employees reporting in good faith.
1
However, there is no explicit evidence of independent investigation processes for whistleblower reports. For ethics complaints, the Corporate Compliance Officer or designees must acknowledge written complaints within seven days, but no median resolution time is provided.
2
Valneva's Anti-Bribery and Anti-Corruption (ABAC) Policy, effective January 2024, is compliant with major international laws (e.g., UK Bribery Act, US FCPA) and includes risk-based screenings of certain third parties.
3
The policy is monitored and reviewed periodically.
4
For third-party verification, Valneva partners with EcoVadis to assess risks and enhance transparency in its supply chain, and conducts screenings of material third parties.
5
Deloitte and PricewaterhouseCoopers Audit provide independent limited assurance on sustainability information and non-financial performance statements, but the overall percentage of ethical claims verified is not specified.
6
Kind to Animals
-40
Valneva has an animal welfare policy that commits to the 3Rs principle (Replacement, Reduction, and Refinement) and adheres to national and international regulations, including the EU Directive 2010/63/EU.
1
The policy details internal procedures for animal testing, including oversight by an Animal-welfare Body, and external testing through qualified Contract Research Organizations (CROs).
2
It also emphasizes training and competency for personnel involved in animal experimentation and care.
3
However, the company conducts pre-clinical studies on animals to assess drug safety, and the policy implies legal mandates for testing override alternatives.
4
Valneva actively participates in industry seminars and congresses, such as the 3R Society, the annual conference of the German Society for Laboratory Animal Science (GV-SOLAS), and the European FELASA Congress.
5
No War, No Weapons
-50
Valneva has multiple supply contracts for its IXIARO vaccine with the U.S. Department of Defense or U.S. Government. These include a $70 million contract
1
, a $32 million contract
2
, and a $32.8 million contract.
3
Based on the company's 2024 revenue of €169.6 million (approximately $181.4 million)
4
, these contracts, totaling $134.8 million, represent approximately 74.3% of the company's revenue. The company's 2024 Sustainability Statement and 2023 Sustainability Report mention alignment with the UN Guiding Principles on Business and Human Rights
5
and the UN Global Compact
6
, respectively, but do not provide details on implementation or third-party audits.
Planet-Friendly Business
-20
Valneva reported total Scope 1, 2, and 3 greenhouse gas emissions of 59,310 tCO₂e in 2024.
1
The company has a target to reduce Scope 1 and 2 emissions by 50% from a 2022 baseline by 2030, and Scope 1 and 2 emissions reduced by 48% from 2019 to 2023.
2
While Valneva participates in the Assessing Low-Carbon Transition (ACT) Initiative, it has not explicitly stated SBTi-validated targets.
3
In 2024, 80% of total energy consumption came from renewable sources, and 100% of electricity contracted by manufacturing and R&D sites was from renewable sources in 2023 and 2024.
4
The company's water use per €1 million net revenue was 315.7 m³ in 2024.
5
In 2024, 65% of waste was recycled, and 73% of waste was diverted from landfill in 2023.
6
All manufacturing sites achieved zero-to-landfill in 2024.
7
The company reported that 76% of its Capital Expenditure was eligible for EU Taxonomy in 2024.
8
Valneva conducted EcoVadis assessments for 96 Tier 1 suppliers in 2024, representing over 80% of purchasing expenditure.
9
The company is conducting feasibility studies for replacing horseshoe crab blood in vaccine testing with recombinant factor C (rFC) technology.
10
No environmental compliance violations were reported in 2024.
11
A climate diagnosis analysis was conducted, including physical and transition risks under different scenarios (Low Carbon, Intermediate, Fossil Fuel Development).
12
Respect for Cultures & Communities
0
Valneva has an Inclusive Language Policy to promote respectful and inclusive communication in job descriptions and advertisements.
1
The company also provides multiple grievance mechanisms, including a Compliance Helpline, email, website, and local Compliance Officers.
2
Safe & Smart Tech
-40
A data breach occurred at a Covid vaccine trial, where email addresses of 4,000 participants were inadvertently shared due to an administrative error.
1
This incident was described as a "massive GDPR breach," leading to notification of relevant authorities and internal re-training of administrative staff at the partner organization.
2
The company's privacy policy outlines user rights, including the ability to access, rectify, erase, and transfer data, object to or restrict processing, and withdraw consent.
3
Data retention periods are specified, such as 30 years for pharmacovigilance data, 10 years for applications, 7 months for medical requests, 12 months for website cookies, and 16 years for clinical trial data.
4
The company mentions compliance with French law, EU Taxonomy Regulation, and GDPR.
5
Valneva also reports on employee security training, including a Code of Conduct & Ethics e-learning platform with quizzes, covering data privacy and cybersecurity.
6
Zero Waste & Sustainable Products
-30
In 2024, 100% of Valneva’s manufacturing sites achieved zero-to-landfill.
1
The company's overall waste diversion rate for 2024 was 65.3%.
2
Valneva reduced hazardous waste generated by 18% and non-hazardous waste by 10% in 2024 compared to 2023.
3
The company aims to use natural resources efficiently and minimize environmental impact throughout product lifecycles, and has implemented initiatives such as a Zero Waste to Landfill project at its Livingston site and sorting non-contaminated plastic laboratory waste in Nantes.
4
Valneva has a target to reduce the proportion of waste sent to landfills from 19% to 2.5% in 2024 at its Livingston site.
5
In 2024, 99% of Valneva’s vaccines’ secondary packaging was recyclable, and 66% of commercial vaccines had plastic-free secondary packaging and blister-free packaging.
6
However, primary packaging is not recyclable.
7
The average recycled content in the packaging of three vaccines was 63% in 2024.
8
The company replaced paper cups, plastic water bottles, and plastic cutlery with reusable options.
9
Valneva plans to define a Sustainable Procurement Policy by 2026, including environmentally friendly criteria for selecting suppliers, and to assess 100% of key suppliers in EcoVadis by 2026.
10